Abstract
Background: Two mRNA COVID-19 vaccines, Pfizer-BioNTech and Moderna, are currently approved in the United States, and one viral-vector vaccine, J&J/Janssen, is authorized for limited use. The Vaccine Adverse Event Reporting System (VAERS) database gathers reports of adverse effects, including anaphylaxis. Objective: In this manuscript, we provide a summary of reported incidence of anaphylaxis rates following administration of the two mRNA and one viral-vector COVID-19 vaccine. Methods: A detailed investigation of the relative risk of anaphylaxis for recipients with or without a prior history of allergy and/or anaphylaxis is also described. Results: Overall reported incidence of anaphylaxis is 4.49 [95% CI: 0.25 – 8.73] cases per million doses administered. Conclusion: The reported risk of anaphylaxis is 1.83 times greater for recipients with prior allergies and no anaphylaxis but 17.70 times greater for recipients with prior allergies and anaphylaxis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
